Research Progress in the Prevention and Treatment of Type 1 Diabetes Mellitus Based on Intestinal Flora and Its Metabolite Short-chain Fatty Acids

doi:10.12114/j.issn.1007-9572.2021.00.085

Abstract

Abstract: Type 1 diabetes mellitus is a chronic autoimmune disease in which directed destruction of pancreatic β cell mediated by T lymphocytes.It is more common in children and adolescents.Studies have shown that the intestinal flora and its metabolites short-chain fatty acids play an important role in the prevention and treatment of T1DM.The regulation of intestinal flora will provide new ideas and approaches for the prevention and treatment of T1DM.This article reviews the research progress of the intestinal flora and its metabolites SCFAs in the prevention and treatment of T1DM and explors the current research status of the T1DM improvement by SCFAs，dietary fiber，probiotics and prebiotics，intestinal flora transplantation and Chinese medicine treatment，which providing reference for clinical application.

Key words: Diabetes mellitus, type 1；intestinal flora；short chain fatty acids；Type 1 diabetes mellitus；Disease treating &, preventing；Review

摘要： 1型糖尿病（T1DM）是由T淋巴细胞介导的胰岛β细胞被定向破坏的慢性自身免疫性疾病，多发于儿童和青少年。研究发现，肠道菌群及其代谢产物短链脂肪酸（SCFAs）在T1DM的预防和治疗中发挥重要作用，肠道菌群调节将为T1DM的防治提供新的思路和方法。本文综述了肠道菌群及其代谢产物SCFAs防治T1DM的研究进展，探究SCFAs、膳食纤维、益生菌和益生元、肠道菌群移植及中药治疗改善T1DM的研究现状，为临床应用提供参考。

关键词: 糖尿病, 1型；肠道菌群；短链脂肪酸；病症防治；综述

SONG Chaojie,ZHANG Xiaoli,CHEN Huanhuan. Research Progress in the Prevention and Treatment of Type 1 Diabetes Mellitus Based on Intestinal Flora and Its Metabolite Short-chain Fatty Acids　[J]. Chinese General Practice, 2021, 24(17): 2230-2235. DOI: 10.12114/j.issn.1007-9572.2021.00.085.
宋超杰,张小莉,陈换换. 基于肠道菌群及其代谢产物短链脂肪酸防治1型糖尿病的研究进展[J]. 中国全科医学, 2021, 24(17): 2230-2235. DOI: 10.12114/j.issn.1007-9572.2021.00.085.

References

［1］LV W，GRAVES D T，HE L H，et al．Depletion of the diabetic gut microbiota resistance enhances stem cells therapy in type 1 diabetes mellitus［J］．Theranostics，2020，10（14）：6500-6516．DOI：10.7150/thno.44113.
［2］DE ALMEIDA JÚNIOR R F，DE SOUZA K S C，GALDINO O A，et al．Chloroquine as a promising adjuvant therapy for type 1 Diabetes Mellitus［J］．Sci Rep，2020，10（1）：12098．DOI：10.1038/s41598-020-69001-2.
［3］International Diabetes Federation.IDF DIABETES ATLAS Ninth edition 2019［EB/OL］．［2020-01-19］．https：//www.idf.org/e-library/epidemio．
［4］ROEP B O，TREE T I.Immune modulation in humans：implications for type 1 diabetes mellitus［J］．Nat Rev Endocrinol，2014，10（4）：229-242．DOI：10.1038/nrendo.2014.2.
［5］PRIMAVERA M，GIANNINI C，CHIARELLI F.Prediction and prevention of type 1 diabetes［J］．Front Endocrinol （Lausanne），2020，11：248．DOI：10.3389/fendo.2020.00248.
［6］CRAIG M E，KIM K W，ISAACS S R，et al．Early-life factors contributing to type 1 diabetes［J］．Diabetologia，2019，62（10）：1823-1834．DOI：10.1007/s00125-019-4942-x.
［7］MA Q T，LI Y Q，WANG J K，et al．Investigation of gut microbiome changes in type 1 diabetic mellitus rats based on high-throughput sequencing［J］．Biomedecine Pharmacother，2020，124：109873．DOI：10.1016/j.biopha.2020.109873.
［8］DURAZZO M，FERRO A，GRUDEN G.Gastrointestinal microbiota and type 1 diabetes mellitus：the state of art［J］．J Clin Med，2019，8（11）：E1843．DOI：10.3390/jcm8111843.
［9］BIBBÒ S，DORE M P，PES G M，et al．Is there a role for gut microbiota in type 1 diabetes pathogenesis?［J］．Ann Med，2017，49（1）：11-22．DOI：10.1080/07853890.2016.1222449.
［10］ABDELLATIF A M，SARVETNICK N E.Current understanding of the role of gut dysbiosis in type 1 diabetes［J］．J Diabetes，2019，11（8）：632-644．DOI：10.1111/1753-0407.12915.
［11］VATANEN T，FRANZOSA E A，SCHWAGER R，et al．The human gut microbiome in early-onset type 1 diabetes from the TEDDY study［J］．Nature，2018，562（7728）：589-594．DOI：10.1038/s41586-018-0620-2.
［12］NEEDELL J C，IR D，ROBERTSON C E，et al．Maternal treatment with short-chain fatty acids modulates the intestinal microbiota and immunity and ameliorates type 1 diabetes in the offspring［J］．PLoS One，2017，12（9）：e0183786．DOI：10.1371/journal.pone.0183786.
［13］WU C F，PAN L L，NIU W Y，et al．Modulation of gut microbiota by low methoxyl pectin attenuates type 1 diabetes in non-obese diabetic mice［J］．Front Immunol，2019，10：1733．DOI：10.3389/fimmu.2019.01733.
［14］HANSEN C H F，LARSEN C S，PETERSSON H O，et al．Targeting gut microbiota and barrier function with prebiotics to alleviate autoimmune manifestations in NOD mice［J］．Diabetologia，2019，62（9）：1689-1700．DOI：10.1007/s00125-019-4910-5.
［15］HO J，NICOLUCCI A C，VIRTANEN H，et al．Effect of prebiotic on microbiota，intestinal permeability，and glycemic control in children with type 1 diabetes［J］．J Clin Endocrinol Metab，2019，104（10）：4427-4440．DOI：10.1210/jc.2019-00481.
［16］BOERNER B P，SARVETNICK N E.Type 1 diabetes：role of intestinal microbiome in humans and mice［J］．Ann N Y Acad Sci，2011，1243：103-118．DOI：10.1111/j.1749-6632.2011.06340.x.
［17］GOODRICH J K，WATERS J L，POOLE A C，et al．Human genetics shape the gut microbiome［J］．Cell，2014，159（4）：789-799．DOI：10.1016/j.cell.2014.09.053.
［18］KOENIG J E，SPOR A，SCALFONE N，et al．Succession of microbial consortia in the developing infant gut microbiome［J］．Proc Natl Acad Sci U S A，2011，108（Suppl 1）：4578-4585．DOI：10.1073/pnas.1000081107.
［19］GUARNER F，MALAGELADA J R.Gut flora in health and disease［J］．Lancet，2003，361（9356）：512-519．DOI：10.1016/s0140-6736（03）12489-0.
［20］AHMED Z，VOHRA M S，KHAN M N，et al．Antimicrobial role of Lactobacillus species as potential probiotics against enteropathogenic bacteria in chickens［J］．J Infect Dev Ctries，2019，13（2）：130-136．DOI：10.3855/jidc.10542.
［21］DEDRICK S，SUNDARESH B，HUANG Q，et al．The role of gut microbiota and environmental factors in type 1 diabetes pathogenesis［J］．Front Endocrinol （Lausanne），2020，11：78．DOI：10.3389/fendo.2020.00078.
［22］BULGART H R，NECZYPOR E W，WOLD L E，et al．Microbial involvement in Alzheimer disease development and progression［J］．Mol Neurodegener，2020，15（1）：42．DOI：10.1186/s13024-020-00378-4.
［23］COHEN L J，CHO J H，GEVERS D，et al．Genetic factors and the intestinal microbiome guide development of microbe-based therapies for inflammatory bowel diseases［J］．Gastroenterology，2019，156（8）：2174-2189．DOI：10.1053/j.gastro.2019.03.017.
［24］BIASSONI R，DI MARCO E，SQUILLARIO M，et al．Gut microbiota in T1DM-onset pediatric patients：machine-learning algorithms to classify microorganisms as disease linked［J］．J Clin Endocrinol Metab，2020，105（9）：dgaa407．DOI：10.1210/clinem/dgaa407.
［25］DEMIRCI M，BAHAR TOKMAN H，TANER Z，et al．Bacteroidetes and Firmicutes levels in gut microbiota and effects of hosts TLR2/TLR4 gene expression levels in adult type 1 diabetes patients in Istanbul，Turkey［J］．J Diabetes Complications，2020，34（2）：107449．DOI：10.1016/j.jdiacomp.2019.107449.
［26］MURRI M，LEIVA I，GOMEZ-ZUMAQUERO J M，et al．Gut microbiota in children with type 1 diabetes differs from that in healthy children：a case-control study［J］．BMC Med，2013，11：46．DOI：10.1186/1741-7015-11-46.
［27］SOYUCEN E，GULCAN A，AKTUGLU-ZEYBEK A C，et al．Differences in the gut microbiota of healthy children and those with type 1 diabetes［J］．Pediatr Int，2014，56（3）：336-343．DOI：10.1111/ped.12243.
［28］PINTO E，ANSELMO M，CALHA M，et al．The intestinal proteome of diabetic and control children is enriched with different microbial and host proteins［J］．Microbiology （Reading），2017，163（2）：161-174．DOI：10.1099/mic.0.000412.
［29］DE GOFFAU M C，LUOPAJÄRVI K，KNIP M，et al．Fecal microbiota composition differs between children with β-cell autoimmunity and those without［J］．Diabetes，2013，62（4）：1238-1244．DOI：10.2337/db12-0526.
［30］QI C J，ZHANG Q，YU M，et al．Imbalance of fecal microbiota at newly diagnosed type 1 diabetes in Chinese children［J］．Chin Med J （Engl），2016，129（11）：1298-1304．DOI：10.4103/0366-6999.182841.
［31］HUANG Y，LI S C，HU J，et al．Gut microbiota profiling in Han Chinese with type 1 diabetes［J］．Diabetes Res Clin Pract，2018，141：256-263．DOI：10.1016/j.diabres.2018.04.032.
［32］PATTERSON E，MARQUES T M，O'SULLIVAN O，et al．Streptozotocin-induced type-1-diabetes disease onset in Sprague-Dawley rats is associated with an altered intestinal microbiota composition and decreased diversity［J］．Microbiology （Reading），2015，161（Pt 1）：182-193．DOI：10.1099/mic.0.082610-0.
［33］LI X，ATKINSON M A.The role for gut permeability in the pathogenesis of type 1 diabetes——a solid or leaky concept?［J］．Pediatr Diabetes，2015，16（7）：485-492．DOI：10.1111/pedi.12305.
［34］JAAKKOLA I，JALKANEN S，HÄNNINEN A.Diabetogenic T cells are primed both in pancreatic and gut-associated lymph nodes in NOD mice［J］．Eur J Immunol，2003，33（12）：3255-3264．DOI：10.1002/eji.200324405.
［35］ROUND J L，MAZMANIAN S K.Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota［J］．Proc Natl Acad Sci U S A，2010，107（27）：12204-12209．DOI：10.1073/pnas.0909122107.
［36］LUO A N，LEACH S T，BARRES R，et al．The microbiota and epigenetic regulation of T helper 17/regulatory T cells：in search of a balanced immune system［J］．Front Immunol，2017，8：417．DOI：10.3389/fimmu.2017.00417.
［37］BRUGMAN S，KLATTER F A，VISSER J T，et al．Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat.Is the gut flora involved in the development of type 1 diabetes?［J］．Diabetologia，2006，49（9）：2105-2108．DOI：10.1007/s00125-006-0334-0.
［38］PEARSON J A，TAI N W，EKANAYAKE-ALPER D K，et al．Norovirus changes susceptibility to type 1 diabetes by altering intestinal microbiota and immune cell functions［J］．Front Immunol，2019，10：2654．DOI：10.3389/fimmu.2019.02654.
［39］MACHATE D J，FIGUEIREDO P S，MARCELINO G，et al．Fatty acid diets：regulation of gut microbiota composition and obesity and its related metabolic dysbiosis［J］．Int J Mol Sci，2020，21（11）：E4093．DOI：10.3390/ijms21114093.
［40］ROY R，NGUYEN-NGO C，LAPPAS M.Short-chain fatty acids as novel therapeutics for gestational diabetes［J］．J Mol Endocrinol，2020，65（2）：21-34．DOI：10.1530/JME-20-0094.
［41］ZHOU C，LI L Z，LI T M，et al．SCFAs induce autophagy in intestinal epithelial cells and relieve colitis by stabilizing HIF-1α［J］．J Mol Med （Berl），2020，98（8）：1189-1202．DOI：10.1007/s00109-020-01947-2.
［42］MARIÑO E，RICHARDS J L，MCLEOD K H，et al．Erratum：Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes［J］．Nat Immunol，2017，18（11）：1271．DOI：10.1038/ni1117-1271c.
［43］HEALEY G，MURPHY R，BUTTS C，et al．Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic：a randomised，double-blind，placebo-controlled，cross-over，human intervention study［J］．Br J Nutr，2018，119（2）：176-189．DOI：10.1017/S0007114517003440.
［44］JUNG T H，JEON W M，HAN K S.In vitro effects of dietary inulin on human fecal microbiota and butyrate production［J］．J Microbiol Biotechnol，2015，25（9）：1555-1558．DOI：10.4014/jmb.1505.05078.
［45］CHEN K，CHEN H，FAAS M M，et al．Specific inulin-type fructan fibers protect against autoimmune diabetes by modulating gut immunity，barrier function，and microbiota homeostasis［J］．Mol Nutr Food Res，2017，61（8）．DOI：10.1002/mnfr.201601006.
［46］WU C F，PAN L L，LUO Y，et al．Low methoxyl pectin protects against autoimmune diabetes and associated caecal dysfunction［J］．Mol Nutr Food Res，2019，63（21）：e1900307．DOI：10.1002/mnfr.201900307.
［47］GUDI R，PEREZ N，JOHNSON B M，et al．Complex dietary polysaccharide modulates gut immune function and microbiota，and promotes protection from autoimmune diabetes［J］．Immunology，2019，157（1）：70-85．DOI：10.1111/imm.13048.
［48］DE OLIVEIRA G L V，LEITE A Z，HIGUCHI B S，et al．Intestinal dysbiosis and probiotic applications in autoimmune diseases［J］．Immunology，2017，152（1）：1-12．DOI：10.1111/imm.12765.
［49］CHIBBAR R，DIELEMAN L A.The gut microbiota in celiac disease and probiotics［J］．Nutrients，2019，11（10）：E2375．DOI：10.3390/nu11102375.
［50］ZHUGE A X，LI B，YUAN Y，et al．Lactobacillus salivarius LI01 encapsulated in alginate-pectin microgels ameliorates D-galactosamine-induced acute liver injury in rats［J］．Appl Microbiol Biotechnol，2020，104（17）：7437-7455．DOI：10.1007/s00253-020-10749-y.
［51］CALCINARO F，DIONISI S，MARINARO M，et al．Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse［J］．Diabetologia，2005，48（8）：1565-1575．DOI：10.1007/s00125-005-1831-2.
［52］ABDELAZEZ A，ABDELMOTAAL H，EVIVIE S E，et al．Screening potential probiotic characteristics of Lactobacillus brevis strains in vitro and intervention effect on type I diabetes in vivo［J］．Biomed Res Int，2018，2018：7356173．DOI：10.1155/2018/7356173.
［53］LE T K，HOSAKA T，NGUYEN T T，et al．Bifidobacterium species lower serum glucose，increase expressions of insulin signaling proteins，and improve adipokine profile in diabetic mice［J］．Biomed Res，2015，36（1）：63-70．DOI：10.2220/biomedres.36.63.
［54］DOLPADY J，SORINI C，DI PIETRO C，et al．Oral probiotic VSL#3 prevents autoimmune diabetes by modulating microbiota and promoting indoleamine 2，3-dioxygenase-enriched tolerogenic intestinal environment［J］．J Diabetes Res，2016，2016：7569431．DOI：10.1155/2016/7569431.
［55］MAUVAIS F X，DIANA J，VAN ENDERT P.Beta cell antigens in type 1 diabetes：triggers in pathogenesis and therapeutic targets［J］．F1000Res，2016，5：F1000 Faculty Rev-F1000 Faculty 728．DOI：10.12688/f1000research.7411.1.
［56］UUSITALO U，LIU X，YANG J M，et al．Association of early exposure of probiotics and islet autoimmunity in the TEDDY study［J］．JAMA Pediatr，2016，170（1）：20-28．DOI：10.1001/jamapediatrics.2015.2757.
［57］GROELE L，SZAJEWSKA H，SZYPOWSKA A.Effects of Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 on beta-cell function in children with newly diagnosed type 1 diabetes：protocol of a randomised controlled trial［J］．BMJ Open，2017，7（10）：e017178．DOI：10.1136/bmjopen-2017-017178.
［58］ROBERFROID M，GIBSON G R，HOYLES L，et al．Prebiotic effects：metabolic and health benefits［J］．Br J Nutr，2010，104（Suppl 2）：S1-63．DOI：10.1017/S0007114510003363.
［59］HARBISON J E，ROTH-SCHULZE A J，GILES L C，et al．Gut microbiome dysbiosis and increased intestinal permeability in children with islet autoimmunity and type 1 diabetes：a prospective cohort study［J］．Pediatr Diabetes，2019，20（5）：574-583．DOI：10.1111/pedi.12865.
［60］MITSOU E K，KOUGIA E，NOMIKOS T，et al．Effect of banana consumption on faecal microbiota：a randomised，controlled trial［J］．Anaerobe，2011，17（6）：384-387．DOI：10.1016/j.anaerobe.2011.03.018.
［61］TIAN D D，XU X Q，PENG Q，et al．Effects of banana powder （Musa acuminata Colla） on the composition of human fecal microbiota and metabolic output using in vitro fermentation［J］．J Food Sci，2020．DOI：10.1111/1750-3841.15324.
［62］XIAO L，VAN'T LAND B，ENGEN P A，et al．Human milk oligosaccharides protect against the development of autoimmune diabetes in NOD-mice［J］．Sci Rep，2018，8（1）：3829．DOI：10.1038/s41598-018-22052-y.
［63］VISSER J T，LAMMERS K，HOOGENDIJK A，et al．Restoration of impaired intestinal barrier function by the hydrolysed casein diet contributes to the prevention of type 1 diabetes in the diabetes-prone BioBreeding rat［J］．Diabetologia，2010，53（12）：2621-2628．DOI：10.1007/s00125-010-1903-9.
［64］PENG J，NARASIMHAN S，MARCHESI J R，et al．Long term effect of gut microbiota transfer on diabetes development［J］．J Autoimmun，2014，53：85-94．DOI：10.1016/j.jaut.2014.03.005.
［65］VALLADARES R，SANKAR D，LI N，et al．Lactobacillus johnsonii N6.2 mitigates the development of type 1 diabetes in BB-DP rats［J］．PLoS One，2010，5（5）：e10507．DOI：10.1371/journal.pone.0010507.
［66］田雨，丁艳平，邵宝平，等．黄芪等药食同源类中药作为功能性食品与肠道菌群的相互作用［J］．中国中药杂志，2020，45（11）：2486-2492．DOI：10.19540/j.cnki.cjcmm.20200119.401.
TIAN Y，DING Y P，SHAO B P，et al．Interaction between homologous functional food Astragali Radix and intestinal flora［J］．Zhongguo Zhong Yao Za Zhi，2020，45（11）：2486-2492．DOI：10.19540/j.cnki.cjcmm.20200119.401.
［67］XU J，LIAN F M，ZHAO L H，et al．Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal For Mula［J］．ISME J，2015，9（3）：552-562．DOI：10.1038/ismej.2014.177.
［68］TONG X L，XU J，LIAN F M，et al．Structural alteration of gut microbiota during the amelioration of human type 2 diabetes with hyperlipidemia by metformin and a traditional Chinese herbal for Mula：a multicenter，randomized，open label clinical trial［J］．mBio，2018，9（3）：e02392-02317．DOI：10.1128/mBio.02392-17.
［69］YUAN T M，YIN Z J，YAN Z X，et al．Tetrahydrocurcumin ameliorates diabetes profiles of db/db mice by altering the composition of gut microbiota and up-regulating the expression of GLP-1 in the pancreas［J］．Fitoterapia，2020，146：104665．DOI：10.1016/j.fitote.2020.104665.
［70］YAN H L，LU J M，WANG Y F，et al．Intake of total saponins and polysaccharides from Polygonatum kingianum affects the gut microbiota in diabetic rats［J］．Phytomedicine，2017，26：45-54．DOI：10.1016/j.phymed.2017.01.007.
［71］XIAO S W，LIU C，CHEN M J，et al．Scutellariae Radix and coptidis rhizoma ameliorate glycolipid metabolism of type 2 diabetic rats by modulating gut microbiota and its metabolites［J］．Appl Microbiol Biotechnol，2020，104（1）：303-317．DOI：10.1007/s00253-019-10174-w.
［72］游玉明，任亭，张世奇，等．花椒麻味物质对糖尿病大鼠肠道微生态的影响［J］．营养学报，2017，39（2）：170-176.
YOU Y M，REN T，ZHANG S Q，et al．Effect of Zanthoxylum alkylamide on intestinal microecology in diabetic rats［J］．Acta Nutrimenta Sinica，2017，39（2）：170-176.
［73］任廷远，陆敏涛，黄涛，等．花椒精油对1型糖尿病小鼠肠道健康的影响［J］．中国粮油学报，2020，35（8）：88-96.
REN T Y，LU M T，HUANG T，et al．Effects of essential oil from zanthoxylum bungeanum on intestinal health of typeⅰ diabetic mice［J］．Journal of the Chinese Cereals and Oils Association，2020，35（8）：88-96.

[1]	ZHANG Yunuo, LI Ruibin, WANG Wei. Correlation Analysis of Serum Nesfatin-1 and Ghrelin Levels with Glycolipid Metabolism and Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2025, 28(26): 3264-3270.
[2]	ZHANG Ruimin, DONG Zheyi, LI Shuang, WANG Qian, CHEN Xiangmei. Traditional Chinese Medicine Factors Associated with Diabetic Nephropathy Diagnosed by Renal Biopsy [J]. Chinese General Practice, 2025, 28(26): 3307-3313.
[3]	TANG Shangfeng, HUANG Yangzhen, ZHENG Yanxi, PAN Yangyang, XIONG Zhongbao, QING Hua, SONG Jia, WEI Yilin, DONG Heng, WANG Chunying, CHEN Manwei, ZHANG Kangkang. Specification for the Integration of Healthcare and Prevention Services in Diabetes at the Primary Level [J]. Chinese General Practice, 2025, 28(25): 3096-3103.
[4]	YANG Chen, CHEN Tong, ZHANG Lifang, ZHANG Hongxu, LI Pengfei, ZHANG Xuejuan. Prognostic Impact of Dapagliflozin in Elderly Breast Cancer Survivors with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes [J]. Chinese General Practice, 2025, 28(24): 3053-3058.
[5]	WANG Rupeng, NAN Jing, HU Yiran, YANG Shenghua, JIN Zening. Predictive Value of the Triglyceride-Glucose Body Mass Index for Slow Flow/No-reflow Phenomenon in Patients with Type 2 Diabetes Mellitus and Acute Myocardial Infarction Undergoing Emergency Percutaneous Coronary Intervention [J]. Chinese General Practice, 2025, 28(24): 2985-2992.
[6]	LIU Yueying, WANG Xueli, LIU Yuqiu, WEI Limin. Correlation of Fasting C-peptide to Diabetes Duration Ration and Type 2 Diabetes Mellitus Combined with Metabolism-related Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(23): 2852-2860.
[7]	WANG Peng, QIU Lixia, XU Shanshan, ZHANG Yang, ZHANG Jing, DU Xiaofei. Advances in the Co-management of Metabolism Dysfunction-associated Fatty Liver Disease and Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2025, 28(23): 2846-2851.
[8]	BAI Xue, CHEN Qianqian, LI Jie. Innovative Practices in Chronic Disease Management: a New Model for Generalist-Specialist Combination Management of Diabetes and Metabolic Dysfunction-associated Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(23): 2841-2845.
[9]	TANG Xiaorui, XU Jingjing, GU Zijun, WANG Qingyu, LIN Zheng, ZHU Qiurui, LEI Yang. The Reliability and Validity of the Chinese Version of Self-Care of Diabetes Inventory [J]. Chinese General Practice, 2025, 28(21): 2643-2651.
[10]	WANG Ying, YAN Yijun, LIU Lei, HU Yumin, ZHANG Yang, LIU Kai, JIANG Boren. Effects of Resistance Exercise Combined with Nutritional Intervention on Blood Glucose Stability in Elderly Patients with Type 2 Diabetes Mellitus with Sarcopenia [J]. Chinese General Practice, 2025, 28(21): 2604-2610.
[11]	MA Panpan, WANG Sijing, YOU Na, DING Dafa, LU Yibing. Efficacy and Safety of Danuglipron and Orforglipron in the Treatment of Type 2 Diabetes Mellitus: a Meta-analysis [J]. Chinese General Practice, 2025, 28(21): 2679-2685.
[12]	JIN Yan, YANG Yang, WANG Lulu, ZHENG Qingwan, LI Xinyan, ZHANG Ning. Effects of Exercise Training after Bariatric Surgery on Cardiopulmonary Function in Patients with Type 2 Diabetes Mellitus and Obesity: a Randomized Controlled Trial [J]. Chinese General Practice, 2025, 28(21): 2611-2617.
[13]	FU Rong, SHI Lei, HE Feiying. Comorbidity of Diabetes and Depression in Middle-aged and Elderly People: the Impact of Sleep, Exercise, and Social Activities [J]. Chinese General Practice, 2025, 28(20): 2491-2500.
[14]	HUANG Zhijie, MAI Zhihua, WANG Haoxiang, HE Yuming, DENG Qiaoyan, DAI Ranran, ZHOU Zhiheng. Multimorbidity of Hypertension, Diabetes, and Dyslipidemia and Influencing Factors of Family Function among the Elderly [J]. Chinese General Practice, 2025, 28(16): 2001-2010.
[15]	ZHAO Xiaoxiao, KE Lixin, XUN Yangqin, WANG Haibo, GAO Wulin, QIAO Tianci, LU Xiaohui, WU Jibiao, LU Cuncun. Investigation and Future Trend Prediction of Disease Burden of Elderly Type 2 Diabetes Mellitus Globally and in China from 1990 to 2021 [J]. Chinese General Practice, 2025, 28(16): 2050-2058.